Publication: 4755

Physical activity and molecular residual disease (MRD) in stage III colon cancer: findings from CALGB (Alliance)/SWOG 80702.
   Google Scholar   
Citation:
Meeting Instance:
ASCO GI 2026
Year:
2026
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub-ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
Natera, Pfizer;  
Grants:
U10CA180821, U10CA180882, U24CA196171; U10CA180863, CCS 707213 (CCTG); U10CA180820 (ECOG-ACRIN), U10CA180868 (NRG Oncology); U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                                         
Networks:
HEARTLAND, LAPS-IL057, LAPS-MA036, LAPS-MO011, NY141, OH027   
Study
CALGB-80702
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: